Understand the source comparison
Semax Amidate Research Review: Study Design Comparison
Different research protocols produce meaningfully different outcomes based on dose, frequency, and administration route. This table synthesizes findings from peer-reviewed Semax Amidate research published between 2015 and 2024. RCT. Healthy Adults (2021) 600 m
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different research protocols produce meaningfully different outcomes based on dose, frequency, and administration route. This table synthesizes findings from peer-reviewed Semax Amidate research published between 2015 and 2024.
- RCT. Healthy Adults (2021)
- 600 mcg (300 mcg × 2)
- Intranasal
- Attention (Stroop Test)
- 18% improvement, p < 0.01
- Most robust evidence for pro-attentional effects in cognitively normal population
- RCT. Mild Cognitive Impairment (2018)
- Memory (MoCA scores)
- +2.8 points vs +0.4 placebo
- Strongest effect size seen in populations with baseline cognitive deficit
- Open-Label Trial (2020)
- 300 mcg
- Verbal Fluency
- 12% increase word generation
- Moderate effect; no placebo control limits interpretation
- Animal Model. Neuroprotection (2019)
- 50 mcg equivalent
- Hippocampal BDNF expression
- 1.8× baseline at 24h
- Mechanism confirmed but human dose equivalence uncertain
- Observational. Stroke Recovery (2017)
- 900 mcg (300 mcg × 3)
- Functional recovery (Barthel Index)
- 25% improvement vs standard care
- Promising but lacks randomization; confounded by rehabilitation intensity
- Intranasal administration at 300–600 mcg daily appears optimal for cognitive enhancement research based on current evidence. Higher doses (900 mcg+) show diminishing returns in attention tasks, and subcutaneous administration has not demonstrated superior bioavailability to justify the invasiveness for research purposes.